Q-omics provides the consensus-scored MYC profile across patient tissues and cancer cell-line models. MYC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYC is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, MYC RNA expression shows 19,303 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where MYC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYC survival associations across molecular data types. MYC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYC RNA expression–survival associations across cancer types. High MYC expression shows unfavorable associations in ACC, BLCA, KIRP and UCEC, but favorable associations in LGG and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYC RNA expression.
This table summarizes MYC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MYC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYC shows lower tumor expression in BLCA, UCEC and BRCA and higher tumor expression in COAD, KIRP and KIRC. The COAD box plot shows higher MYC RNA expression in tumor versus normal tissue (log2 FC = +2.393, t-test p < 0.001).
This table shows molecular features associated with MYC in patient tissues and cancer cell lines. In patient samples, MYC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
